和黄医药核心产品增长强劲,开启可持续盈利篇章

太平洋证券
Yesterday

呋喹替尼海外市场强劲增长,多适应症拓展贡献增量公司2024年肿瘤/免疫业务综合收入3.63亿美元,其中肿瘤产品综合收入2.72亿美元,同比增长65.35%,主要得益于呋喹替尼在海外市场的快速放量。2024年呋喹替尼(爱优特)国内销售收入1.15亿美元,同比18增25长%。7%;呋喹替尼(Fruzaqla)海外销售收入2.91亿美元,同比增长2024年12月,基于呋喹替尼的II期临床研究...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10